Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

Ajay K. Nooka; Jonathan L. Kaufman; Cesar Rodriguez; Andrzej Jakubowiak; Yvonne Efebera; Brandi Reeves; Tanya M. Wildes; Sarah A. Holstein; Larry D. Anderson; Ashraf Badros; Leyla Shune; Ajai Chari; Huiling Pei; Annelore Cortoos; Sharmila Patel; Thomas S. Lin; Peter M. Voorhees; Saad Z. Usmani; Paul G. Richardson

doi:10.1111/bjh.19386

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson

Research output: Contribution to journal › Article › peer-review

Abstract

Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients.

Original language	English
Pages (from-to)	2227-2232
Number of pages	6
Journal	British Journal of Haematology
Volume	204
Issue number	6
DOIs	https://doi.org/10.1111/bjh.19386
State	Published - Jun 2024

Keywords

antibody therapy
clinical trials
complete remission
haematological malignancy
minimal residual disease
multiple myeloma

Access to Document

10.1111/bjh.19386

Cite this

Nooka, A. K., Kaufman, J. L., Rodriguez, C., Jakubowiak, A., Efebera, Y., Reeves, B., Wildes, T. M., Holstein, S. A., Anderson, L. D., Badros, A., Shune, L., Chari, A., Pei, H., Cortoos, A., Patel, S., Lin, T. S., Voorhees, P. M., Usmani, S. Z., & Richardson, P. G. (2024). Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British Journal of Haematology, 204(6), 2227-2232. https://doi.org/10.1111/bjh.19386

@article{621b84d644b94aafaee71defc850aa61,

title = "Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study",

abstract = "Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients.",

keywords = "antibody therapy, clinical trials, complete remission, haematological malignancy, minimal residual disease, multiple myeloma",

author = "Nooka, {Ajay K.} and Kaufman, {Jonathan L.} and Cesar Rodriguez and Andrzej Jakubowiak and Yvonne Efebera and Brandi Reeves and Wildes, {Tanya M.} and Holstein, {Sarah A.} and Anderson, {Larry D.} and Ashraf Badros and Leyla Shune and Ajai Chari and Huiling Pei and Annelore Cortoos and Sharmila Patel and Lin, {Thomas S.} and Voorhees, {Peter M.} and Usmani, {Saad Z.} and Richardson, {Paul G.}",

note = "Publisher Copyright: {\textcopyright} 2024 Janssen Scientific Affairs, LLC. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2024",

month = jun,

doi = "10.1111/bjh.19386",

language = "English",

volume = "204",

pages = "2227--2232",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

Nooka, AK, Kaufman, JL, Rodriguez, C, Jakubowiak, A, Efebera, Y, Reeves, B, Wildes, TM, Holstein, SA, Anderson, LD, Badros, A, Shune, L, Chari, A, Pei, H, Cortoos, A, Patel, S, Lin, TS, Voorhees, PM, Usmani, SZ & Richardson, PG 2024, 'Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study', British Journal of Haematology, vol. 204, no. 6, pp. 2227-2232. https://doi.org/10.1111/bjh.19386

TY - JOUR

T1 - Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

AU - Nooka, Ajay K.

AU - Kaufman, Jonathan L.

AU - Rodriguez, Cesar

AU - Jakubowiak, Andrzej

AU - Efebera, Yvonne

AU - Reeves, Brandi

AU - Wildes, Tanya M.

AU - Holstein, Sarah A.

AU - Anderson, Larry D.

AU - Badros, Ashraf

AU - Shune, Leyla

AU - Chari, Ajai

AU - Pei, Huiling

AU - Cortoos, Annelore

AU - Patel, Sharmila

AU - Lin, Thomas S.

AU - Voorhees, Peter M.

AU - Usmani, Saad Z.

AU - Richardson, Paul G.

PY - 2024/6

Y1 - 2024/6

N2 - Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients.

AB - Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients.

KW - antibody therapy

KW - clinical trials

KW - complete remission

KW - haematological malignancy

KW - minimal residual disease

KW - multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85188517596&partnerID=8YFLogxK

U2 - 10.1111/bjh.19386

DO - 10.1111/bjh.19386

M3 - Article

C2 - 38504552

AN - SCOPUS:85188517596

SN - 0007-1048

VL - 204

SP - 2227

EP - 2232

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

Abstract

Keywords

Access to Document

Fingerprint

Cite this